Par Health, a generic drugmaker headquartered in St. Louis, has issued a voluntary nationwide recall of 22 lots of Argatroban Injection, an IV blood thinner used in hospitals, because the medication may contain particles. The particles may include cellulose, polystyrene, polyethylene terephthalate (a common plastic), stopper material, and possibly stainless steel. The recall was posted to the U.S. Food and Drug Administration (FDA) website on October 14, 2026, and is the company’s third U.S. product recall in about a month.
What’s Being Recalled?
The recall covers 22 lots of Par Health Argatroban Injection 250 mg/2.5 mL (100 mg/mL). The product was shipped to wholesalers and hospitals between December 30, 2024, and May 5, 2026. Some of the affected lots are set to expire in October 2026. Argatroban is used to treat or prevent blood clots in patients with heparin-induced thrombocytopenia, a serious reaction to the common blood thinner heparin. It is given by IV in a hospital setting and is not sold at retail pharmacies. The full list of affected lot numbers is included in the company’s announcement on the FDA website.
Why Was This Product Recalled?
Foreign particles in an injected drug can be life-threatening because they travel directly into the bloodstream. They can cause blood clots in the lungs, block other blood vessels, or lead to inflammation of the vein walls. Par Health says it has not received any reports of adverse events tied to the recalled lots. This recall follows two others by the company in recent weeks, both over possible particle contamination. On September 18, 2026, it recalled two lots of the IV sedative dexmedetomidine. On October 8, 2026, it recalled two lots of the IV anesthetic Brevital sodium.
What Should You Do?
Wholesalers and hospital pharmacies with the recalled product in stock are being told to stop using it immediately. Par Health is working with healthcare logistics company Inmar to collect the affected lots. Patients cannot buy this drug on their own, so there is nothing to check at home. However, if you or a loved one received argatroban during a recent hospital stay and you have concerns, talk with your doctor. Side effects can be reported to the FDA’s MedWatch program at 1-800-FDA-1088.
Source: https://www.fiercepharma.com/pharma/par-health-recalls-22-lots-iv-blood-thinner-its-3rd-recall-month
